Table 3.

Treatment-related adverse events reported in ≥3 patients or Grade ≥3 in the same dose cohorts (dose escalation + cohort expansion) for each combination treatment.

Adverse event	No. of patients (%)
	Mogamulizumab 1 mg/kg + durvalumab 10 mg/kg (n = 19)		Mogamulizumab 1 mg/kg + tremelimumab 10 mg/kg (n = 19)
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Rash maculopapular	7 (36.8)	4 (21.1)	5 (26.3)	2 (10.5)
Fatigue	6 (31.6)	1 (5.3)	3 (15.8)	0
Pruritis	5 (26.3)	0	3 (15.8)	1 (5.5)
Infusion-related reactions	4 (21.1)	0	7 (36.8)	0
Diarrhea	4 (21.1)	0	4 (21.1)	0
Hypothyroidism	3 (15.8)	0	0	0
Stomatitis	1 (5.3)	1 (5.3)	4 (21.1)	0
Rash	1 (5.3)	0	3 (15.8)	1 (5.3)
Colitis	1 (5.3)	1 (5.3)	3 (15.8)	1 (5.3)
Decreased lymphocytes	1 (5.3)	0	1 (5.3)	1 (5.3)
Transaminases increased	1 (5.3)	0	1 (5.3)	1 (5.3)
Autoimmune hepatitis	1 (5.3)	0	1 (5.3)	1 (5.3)
Gastritis	1 (5.3)	1 (5.3)	0	0
Blood CPK increased	1 (5.3)	1 (5.3)	0	0
Hyperglycemia	1 (5.3)	1 (5.3)	0	0
Vomiting	0	0	1 (5.3)	1 (5.3)
Abnormal liver function test	0	0	1 (5.3)	1 (5.3)
Hypertension	0	0	1 (5.3)	1 (5.3)

CPK, creatine phosphokinase.